1. A solid composition for oral administration containing a GLP-1 agonist and a salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid, where the amount of said salt of N- (8- (2-hydroxybenzoyl) amino) caprylic acid is at least 0.6 or at least 0.8 mmol； and said GLP-1 agonist may contain one substituent. The composition of claim 1, wherein said composition is in the form of a tablet. The composition of claim 1, wherein said N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt is N- (8- (2-hydroxybenzoyl) amino) sodium caprylate (SNAC). The composition of claim 1, wherein the amount of said N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt is in the range of 0.6-2.1 mmol, such as, for example, 0.6-1.9 mmol, 0 7-1.7 mmol or 0.8-1.3 mmol. 5. The composition of claim 1, wherein the amount of said N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt is at least 0.6 mmol, such as, for example, selected from the group consisting of at least 0.65 mmol at least 0.7 mmol, at least 0.75 mmol, at least 0.8 mmol, at least 0.8 mmol, at least 0.9 mmol, at least 0.95 mmol, or at least 1 mmol. 6. The composition of claim 1, wherein the amount of said N- (8- (2-hydroxybenzoyl) amino) caprylic acid salt is up to 2.1 mmol, such as, for example, selected from the group consisting of up to 2.1 mmol, up to up to 2 mmol, up to 1.9 mmol, up to 1.8 mmol, up to 1.7 mmol, up to 1.6 mmol, up to 1.5 mmol, up to 1.4 mmol, up to 1, 3 mmol, up to 1.2 mmol and up to 1.1 mmol. 7. The composition of claim 1, wherein the amount of GLP-1 agonist is in the range of 0.01 mg to 100 mg. The composition of claim 1, wherein said GLP-1 agonist is GLP-1 (7-1. Твердая композиция для перорального введения, содержащая агонист GLP-1 и соль N-(8-(2-гидроксибензоил)амино)каприловой кислоты, где количество указанной соли N-(8-(2-гидроксибензоил)амино)каприловой кислоты составляет по меньшей мере 0,6 или по меньшей мере 0,8 ммоль； и указанный агонист GLP-1 возможно содержит один заместитель.2. Композиция по п.1, где ук
